Cobalt(III) Schiff Base Complex for Selective Cancer Cell Cycle Arrest
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current platinum-based chemotherapeutics for cancer, such as oxaliplatin, suffer from significant side effects like nephrotoxicity, ototoxicity, neurotoxicity, hepatotoxicity, and poor selectivity towards cancer cells, necessitating the development of alternative metal-based anticancer agents with reduced toxicity and enhanced efficacy.
Innovation Solution
A non-toxic mononuclear cobalt(III) Schiff base complex, derived from 1,2-diaminocyclohexane and 2,6-diformyl-4-methylphenol, exhibits cytotoxicity against cancer cells by inducing apoptosis via G2-M phase cell cycle arrest in breast cancer cells and G0-G1 phase arrest in colon cancer cells, while maintaining low toxicity to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If platinum-based chemotherapeutics (oxaliplatin) are used to treat cancer, then cancer cell killing efficacy is improved, but toxicity to normal cells (nephrotoxicity, ototoxicity, neurotoxicity, hepatotoxicity) increases
Solution Approach 1:
The patent changes the metal center from platinum to cobalt, altering the chemical parameters of the anticancer agent. This substitution maintains cytotoxicity against cancer cells while reducing toxicity to normal cells, as demonstrated by the Co(III) Schiff base complex achieving IC50 values comparable to oxaliplatin in cancer cell lines but showing minimal toxicity in normal human cell lines
Solution Approach 2:
The patent creates a composite metal complex by combining cobalt ions with organic Schiff base ligands (derived from 1,2-diaminocyclohexane and 2,6-diformyl-4-methylphenol). This composite structure enables the molecule to exhibit anticancer properties through cell cycle arrest and apoptosis induction while avoiding the severe side effects associated with pure platinum-based compounds
2Productivity
If platinum-based chemotherapeutics are used to treat cancer, then cancer cell proliferation inhibition is improved, but selectivity towards cancer cells deteriorates
Solution Approach 1:
The patent modifies the chemical parameters by using cobalt instead of platinum, which changes the interaction mechanism with cancer cells. The Co(III) complex achieves comparable proliferation inhibition (IC50 values of 16.81 μM for MCF-7, 15.27 μM for HCT-116, and 10.04 μM for SW-480) but with improved selectivity, as it does not cause the severe non-cancer cell toxicity associated with platinum drugs
3Productivity
If cobalt(III) Schiff base complex is used at lower concentrations, then cytotoxicity against cancer cells is improved, but toxicity to normal cells may increase
Solution Approach 1:
The patent optimizes the concentration parameter by demonstrating that the cobalt complex achieves effective cytotoxicity at lower concentrations compared to platinum-based drugs. The complex shows IC50 values of 16.81 μM for breast cancer cells and 10.04-15.27 μM for colon cancer cells, while maintaining safety profiles with minimal toxicity to normal human cells at these concentrations
Data Source
AI summary
A significantly non-toxic novel mononuclear cobalt(III)-Schiff base complex (1) capable to induce apoptosis via G2-M cell cycle arrest in human breast cancer cell line MCF-7 and cell cycle arrest of colon cancer cell lines HCT-116 and SW-480 via G0-G1. The Schiff base complex (1) having >99% purity has been synthesized by a facile “One pot” synthesis method and has been characterized with standard spectroscopic techniques. Complex 1 exhibits cytotoxicity (IC50=16.81±1.33 μM) at much lower concentration in comparison to oxaliplatin (IC50=31.4±0.69 μM) against MCF-7 cells and causes apoptosis in colon cancer cell lines HCT-116 and SW-480 by arresting the cell cycle at the G0-G1 phase having IC50 values of 15.27±1.18 μM and 10.04±1.98 μM respectively comparable with the IC50 values of oxaliplatin which are 16.73±1.78 μM and 7.87±1.54 μM respectively after 24 h of treatment without being overly toxic to human PBMCs (IC50=>60 μM). In vivo subacute toxicity (28 days) and systemic chronic toxicity (40 days) studies were carried out in normal Swiss albino mice showed 1 is significantly nontoxic to the host.